Experimental inoculation of CD11c⁺ B1 lymphocytes, CD68⁺ macrophages, or platelet-rich plasma from scrapie-infected sheep into susceptible sheep results in variable infectivity

Najiba Mammadova¹², Eric D. Cassmann¹², S. Jo Moore¹², Eric M. Nicholson¹ and Justin J. Greenlee¹,*

INTRODUCTION

Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of naturally occurring neurodegenerative disorders that include scrapie in sheep and goats, bovine spongiform encephalopathy (BSE), chronic wasting disease (CWD) in cervids and Creutzfeldt–Jakob disease (CJD) in humans. The conformational conversion of the ubiquitously expressed host-encoded cellular prion protein, PrP²⁰, to the pathogenic isoform, PrPSc, and its subsequent accumulation throughout the central nervous system (CNS) is widely known as the characteristic molecular event in TSEs. In classical scrapie and other TSEs, there is a long asymptomatic period between infection and the development of neurological clinical signs, during which there is often progressive replication and accumulation of PrPSc within the lymphoreticular system (e.g. ileal Peyer's patches, tonsil, spleen and retropharyngeal and mesenteric lymph nodes) [1–5]. During this time, PrPSc is detectable within lymphoid tissues for months prior to being detectable in the brain, acting as a significant reservoir of prion infectivity to the environment long before the onset of clinical manifestations of the disease [6]. In line with this, recirculating leukocytes within the lymphoreticular system are probable candidates for uptake, sequestration and dissemination of PrPSc during disease. Indeed, following some of the first evidence of PrPSc accumulation in lymphoid organs of scrapie-infected animals [1–5, 7–9], a number of studies have demonstrated prion infectivity in whole blood and blood fractions in a variety of TSEs in livestock and rodents, and variant CJD in humans [10–22], as well as an association between PrPSc and immune cells [e.g. follicular dendritic cells (FDCs), B lymphocytes and tingible body macrophages] [9, 23–26].

To further investigate the role of various blood components in prion disease transmission, we intracranially inoculated genetically susceptible VRQ/ARQ and ARQ/ARQ sheep with inocula composed of CD11c⁺ B1 lymphocytes, CD68⁺ macrophages, or platelet-rich plasma derived from clinically ill sheep infected with the US no. 13–7 scrapie agent. At the completion of the study, we found that VRQ/ARQ and ARQ/ARQ sheep inoculated with CD11c⁺ B1 lymphocytes and CD68⁺ macrophages developed scrapie with detectable levels of PrPSc in the central nervous system and lymphoreticular system, while those inoculated with platelet-rich plasma did not develop disease and did not have detectable PrPSc by immunohistochemistry or enzyme immunoassay. This study complements and expands on earlier findings that white blood cells harbour prion infectivity, and reports CD11c⁺ B1 lymphocytes and CD68⁺ macrophages as additional targets for possible preclinical detection of prion infection in blood.
sheep with inocula composed of CD11c⁺ B1 lymphocytes, CD68⁺ macrophages, or platelet-rich plasma derived from clinically ill sheep infected with the US no. 13–7 scrapie isolate in ARQ/ARQ sheep [228]. Sheep S300 presented with clinical signs of scrapie 300 days post-inoculation, while sheep B54 and S300 were collected either into syringes containing EDTA or into tubes containing acid citrate dextrose as an anticoagulant. Plasma from whole blood in citrate tubes was initially separated by centrifugation (1500 g for 3 min) and was further centrifuged (5000 g for 5 min) to prepare platelet-rich plasma (16×10⁷ total cells in 4.8 ml of plasma divided among 9 tubes of 1.6×10⁷ cells from sheep B54, and 15.5×10⁷ total cells in 5.8 ml of plasma divided among 6 tubes of 2.5×10⁷ cells from sheep S300). Blood collected into syringes containing EDTA was divided among four 50 ml centrifuge tubes containing 25 ml of cold 0.075% phosphate-buffered saline (PBS)/EDTA and centrifuged for 15 min at 3000 r.p.m. at room temperature. Buffy coat cells collected from centrifuged blood samples were then diluted 1:1 in PBS/EDTA, layered on 15 ml tubes containing 3 ml of 65% percoll solution and further centrifuged for 15 min at 3000 r.p.m. without a break. After centrifugation, buffy coat cells were collected from each tube and all tubes from the same animal were combined into one 15 ml tube, resuspended with PBS/EDTA and centrifuged for 7 min at 1700 r.p.m. Buffy coat cells collected from centrifuged blood samples were washed twice with wash buffer (1% PBS, 0.2% foetal bovine serum (FBS), 2 mM EDTA) and centrifuged for 7 min at 1700 r.p.m. The cell pellets were then resuspended in 10 ml on ice with 1 ml of anti-CD8 (6-87-10), 1 ml of anti-CD4 (17D-13) and 1 ml of anti-CD3 (18-106-6). The tube containing the cell pellets and primary antibodies was then filled with wash buffer and centrifuged for 7 min at 1700 r.p.m. In the meantime, a mixture of 20% goat anti-mouse IgG– or rat anti-mouse IgG1–coupled magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) and 80% wash buffer was created and added to the tube containing the cell pellets. Additional wash buffer (14 ml) was added to the tube and centrifuged for 7 min at 1700 r.p.m. The cell pellet was then resuspended in ~2 ml of wash buffer and separated using a magnetic cell sorting system (MACS, Miltenyi Biotec). Thereafter, to separate B lymphocytes from macrophages, the negative fraction was further centrifuged and incubated for 10 min on ice with 1 ml of anti-CD68 [1–44]. Goat anti-mouse IgG2b– or goat anti-mouse IgG–coupled magnetic beads and additional wash buffer (14 ml) was again added to the tube and centrifuged for 7 min at 1700 r.p.m. The cell pellet was then resuspended in ~2 ml of wash buffer and separated using a magnetic cell sorting system. The positive fraction consisting of macrophages was collected, counted and separated into six

**METHODS**

**Blood donors and recipient sheep**

Two different sheep, S300 and B54, were used as blood donors. S300 was an ARQ/ARQ Suffolk sheep that was IC inoculated with brain homogenate prepared from a whole brain derived from a sheep from the second serial passage of the US no. 13–7 scrapie isolate in ARQ/ARQ sheep [228]. B54 was an ARQ/ARK Barbados sheep that was IC inoculated with brain homogenate prepared from a whole brain derived from a sheep from the fifth serial passage of the US no. 13–7 scrapie isolate in ARQ/ARQ sheep [228]. Sheep S300 presents with detectable levels of PrP Sc in the CNS and lymphoreticular system (LRS), while those inoculated with platelet-rich plasma did not develop disease. This study confirms earlier findings that white blood cells harbour prion infectivity and provides additional targets (i.e. CD11c⁺ B1 lymphocytes and CD68⁺ macrophages) for possible preclinical detection of prion infection in blood.

Recipient sheep of two different genotypes (VRQ/ARQ and ARQ/ARQ) were IC inoculated at 2 months of age with 0.5 ml of inoculum composed of varied blood components (i.e. CD11c⁺ B1 lymphocytes, CD68⁺ macrophages, or platelet-rich plasma) (Table 1) from either donor sheep S300 or B54. The procedure for IC inoculation of lambs has been described previously [229]. All inoculated sheep were housed in biosafety level 2 facilities for 2 weeks following exposure to scrapie. After this period, the sheep were moved to outside pens at the National Animal Disease Center (NADC). The sheep were fed pelleted growth ration and alfalfa hay, and clean water was available ad libitum. Non-inoculated control sheep (n=5) were kept with the scrapie-free flock at the NADC. Animals were observed daily for the development of clinical signs of neurological disease and were euthanized at the onset of unequivocal clinical signs of disease. Clinical signs of disease included abnormalities in gait and/or stance, and ataxia. Incubation period is reported here as the time from inoculation to the time when unequivocal signs of clinical disease are present. Animals were euthanized at the onset of unequivocal clinical signs of disease, or at the end of the observation period (~5 years).

This study consisted of six groups of four animals (three VRQ/ARQ and one ARQ/ARQ) that were inoculated with a specific blood component (macrophages, B1 lymphocytes, or platelet-rich plasma) derived from donor sheep S300 or B54 (n=24 total sheep), as shown in Table 1. At necropsy, duplicate tissue samples were collected and either frozen or stored in 10% buffered neutral formalin. Specifically, tissues were collected comprising representative sections of the brain, spinal cord, retinas, pituitary, trigeminal ganglia, sciatic nerve, third eyelids, tonsils (palatine and pharyngeal), lymph nodes (retropharyngeal, prescapular and popliteal), spleen, esophagus, forestomach, intestines, rectal mucosa, thymus, liver, kidney, urinary bladder, pancreas, salivary gland, thyroid gland, adrenal gland, trachea, lung, turbinates, heart, tongue, masseter muscle, diaphragm, triceps brachii, biceps femoris and psoas major.

**Isolation of blood components**

Jugular venous blood samples (~200 ml) from donor sheep B54 and S300 were collected either into syringes containing EDTA or into tubes containing acid citrate dextrose as an anticoagulant. Plasma from whole blood in citrate tubes was initially separated by centrifugation (1500 g for 3 min) and was further centrifuged (5000 g for 5 min) to prepare platelet-rich plasma (16×10⁷ total cells in 4.8 ml of plasma divided among 9 tubes of 1.6×10⁷ cells from sheep B54, and 15.5×10⁷ total cells in 5.8 ml of plasma divided among 6 tubes of 2.5×10⁷ cells from sheep S300). Blood collected into syringes containing EDTA was divided among four 50 ml centrifuge tubes containing 25 ml of cold 0.075% phosphate-buffered saline (PBS)/EDTA and centrifuged for 15 min at 3000 r.p.m. at room temperature. Buffy coat cells collected from centrifuged blood samples were then diluted 1:1 in PBS/EDTA, layered on 15 ml tubes containing 3 ml of 65% percoll solution and further centrifuged for 15 min at 3000 r.p.m. without a break. After centrifugation, buffy coat cells were collected from each tube and all tubes from the same animal were combined into one 15 ml tube, resuspended with PBS/EDTA and centrifuged for 7 min at 1700 r.p.m. Buffy coat cells collected from centrifuged blood samples were washed twice with wash buffer (1% PBS, 0.2% foetal bovine serum (FBS), 2 mM EDTA) and centrifuged for 7 min at 1700 r.p.m. The cell pellets were then resuspended for 10 min on ice with 1 ml of anti-CD8 (6-87-10), 1 ml of anti-CD4 (17D-13) and 1 ml of anti-CD3 (18-106-6). The tube containing the cell pellets and primary antibodies was then filled with wash buffer and centrifuged for 7 min at 1700 r.p.m. In the meantime, a mixture of 20% goat anti-mouse IgG– or rat anti-mouse IgG1–coupled magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) and 80% wash buffer was created and added to the tube containing the cell pellets. Additional wash buffer (14 ml) was added to the tube and centrifuged for 7 min at 1700 r.p.m. The cell pellet was then resuspended in ~2 ml of wash buffer and separated using a magnetic cell sorting system (MACS, Miltenyi Biotec). Thereafter, to separate B lymphocytes from macrophages, the negative fraction was further centrifuged and incubated for 10 min on ice with 1 ml of anti-CD68 [1–44]. Goat anti-mouse IgG2b– or goat anti-mouse IgG–coupled magnetic beads and additional wash buffer (14 ml) was again added to the tube and centrifuged for 7 min at 1700 r.p.m. The cell pellet was then resuspended in ~2 ml of wash buffer and separated using a magnetic cell sorting system. The positive fraction consisting of macrophages was collected, counted and separated into six
tubes containing PBS to make up $3.16 \times 10^6$ cells $1 \text{ ml}^{-1}$ PBS. To separate B1 lymphocytes from B2 lymphocytes, the negative fraction was labelled with anti-CD11c (17-196) and separated using goat anti-mouse IgG- or rat anti-mouse IgG1- coupled magnetic beads and the MACS cell sorting system. The positive fraction consisting of B1 lymphocytes was collected, counted and separated into 10 tubes containing PBS to make up $3.66 \times 10^6$ cells $1 \text{ ml}^{-1}$ PBS. All primary antibodies were kindly provided by Dr Alan J. Young.

**Immunohistochemistry**

For the detection of PrPSc, slides were stained by an automated immunohistochemistry method using primary antibody F99/F96.7.1 (30) at a concentration of 5 µg ml$^{-1}$, as described previously [31]. Briefly, paraffin-embedded sections (4 µm) were rehydrated using xylene, followed by a decreasing ethanol concentration gradient (100, 90–70%), and a final wash with diH$_2$O. Heat-mediated antigen retrieval was performed using citrate buffer (DAKO Target Retrieval Solution, DAKO Corp., Carpinteria, CA, USA) in an autoclave for 30 min. Slides were then stained with an indirect, biotin-free staining system containing an alkaline phosphatase-labelled secondary antibody (ultraView Universal Alkaline Phosphatase Red Detection Kit, Ventana Medical Systems, Inc., Tucson, AZ, USA) designed for an automated immunostainer (NexES IHC module, Ventana Medical Systems). Slides were

---

**Table 1.** Summary of scrapie transmission results in VRQ/ARQ and ARQ/ARQ sheep IC inoculated with varied blood components (i.e. macrophages, B-cells, or platelets) derived from two different donor sheep, B54 and S300. Genotype refers to recipient sheep that were either PRNP homozygous (ARQ/ARQ) or heterozygous (VRQ/VRQ) at codon 136. Shading highlights all positive results.

| Blood component                  | Donor ID | Genotype | Incubation time (days p.i.) | Clinical signs | WB | EIA | IHC CNS | IHC LRS |
|----------------------------------|----------|----------|-----------------------------|----------------|----|-----|--------|--------|
| CD68+ macrophages                | B54      | 803 VRQ/ARQ | 702                        | POS            | POS| POS| POS    | POS    |
|                                  |          | 805 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  |          | 963 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  | S300     | 944 VRQ/ARQ | 631                        | POS            | POS| POS| POS    | POS    |
|                                  |          | 960 VRQ/ARQ | 652                        | NEG            | NEG| NEG| NEG    | NEG    |
|                                  |          | 967 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
| CD11c+ B1 lymphocytes, DCs and DC precursors | B54      | 941 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  |          | 949 VRQ/ARQ | 1303                       | POS            | POS| POS| POS    | POS    |
|                                  |          | 961 VRQ/ARQ | 616                        | POS            | POS| POS| POS    | POS    |
|                                  | S300     | 928 VRQ/ARQ | 616                        | POS            | POS| POS| POS    | POS    |
|                                  |          | 931 VRQ/ARQ | 702                        | POS            | POS| POS| POS    | POS    |
|                                  |          | 942 VRQ/ARQ | 576                        | POS            | POS| POS| POS    | POS    |
|                                  |          | 826 ARQ/ARQ | 499                        | POS            | POS| POS| POS    | POS    |
| Platelet-rich plasma             | B54      | 812 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  |          | 952 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  |          | 968 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  | S300     | 932 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  |          | 940 VRQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |
|                                  |          | 939 ARQ/ARQ | –                           | NEG            | NEG| NEG| NEG    | NEG    |

EIA, enzyme immunoassay; IHC CNS, immunohistochemistry results in CNS tissues (brain and retina); IHC LRS, immunohistochemistry results in lymphoreticular system (tonsils (palatine and pharyngeal), retropharyngeal and mesenteric lymph node, and spleen); NEG, PrPSc was not detected; p.i., post-inoculation; POS, PrPSc was detected; WB, Western blot.
counterstained with Gill’s haematoxylin and bluing agent (Ventana Medical Systems) and then cover slipped. Images were captured using a Nikon DS camera on a Nikon Eclipse 80i microscope. Micrographs were created using a commercial photo-editing system [Adobe Photoshop and Adobe Illustrator (CC); Adobe Systems].

**Enzyme immunoassay (EIA)**

A commercially available enzyme immunoassay (HerdChek R, IDEXX Laboratories, Inc., Westbrook, ME, USA) was used to screen for the presence of PrPSc in brainstem at the level of the obex and the retropharyngeal lymph node (RPLN). Assays were conducted according to the kit instructions, except that the samples were prepared as a 20% (w/v) tissue homogenate. Cut-off numbers were determined with a negative control per the kit instructions; values greater than the mean optical density (OD) of negative controls +0.180 were considered to be positive for the purposes of screening samples.

**Western blot analysis**

Approximately 0.5 g of brainstem was analysed as described previously, with minor modifications [31]. Samples were homogenized at 4°C in PBS and digested with proteinase K (PK) for 1 h at 37°C. PK digestion was stopped using pefabloc (Roche, Indianapolis, IN, USA) to a final concentration of 1 mg ml⁻¹. One milligram of homogenate was loaded onto precast sodium dodecyl sulfate (SDS) – 12% polyacrylamide gel electrophoresis (PAGE) gels. SDS-PAGE was performed as described by the manufacturer and the proteins were transferred from the gel to a PVDF membrane with transfer buffer at 35 V for 45 min. The membranes were blocked with 3% BSA in TBS-T (Tris-buffered saline +0.1% Tween-20) buffer at 35 V for 45 min. The membranes were blocked with 3% BSA in TBS-T (Tris-buffered saline +0.1% Tween-20) and either incubated with monoclonal antibody Sha31 for 1 h at room temperature or overnight at 4°C. A secondary biotinylated sheep anti-mouse secondary antibody (GE Healthcare, Buckinghamshire, UK) at 0.05 µg ml⁻¹ and a streptavidin/horseradish peroxidase (HRP) conjugate (GE Healthcare, Buckinghamshire, UK) were used according to the manufacturer’s instructions in conjunction with a chemiluminescent detection system (ECL Plus Detection System, GE Healthcare, Buckinghamshire, UK) and imaged using a multimode scanner (GBOX, Synoptics).

**RESULTS**

**Sheep of the VRQ/ARQ and ARQ/ARQ genotypes inoculated with CD11c⁺ B1 lymphocytes and CD68⁺ macrophages developed scrapie**

To determine whether blood components contained sufficient levels of prion infectivity to cause disease, recipient sheep of two different genotypes (VRQ/ARQ and ARQ/ARQ) were IC inoculated with 0.5 ml of inoculum composed of varied blood components (i.e. CD11c⁺ B1 lymphocytes, CD68⁺ macrophages, or platelet-rich plasma) derived from donor sheep S300 or B54, as shown in Table 1. At the completion of the study, 10 of the 24 animals were determined to be scrapie-positive based on accumulation of pathogenic prion protein (PrPSc) by a combination of immunohistochemistry, Western blot and EIA in CNS and non-CNS tissues [tonsils (palatine and pharyngeal), retropharyngeal and mesenteric lymph node and spleen] (Figs 1 and 2). All 10 animals showed clinical signs of scrapie and had a mean incubation period of 613.4 days post-inoculation, with one outlier (animal 949, which developed clinical signs of scrapie at 1303 days post-inoculation). Of the 10 animals, 4 (2 ARQ/ARQ and 2 VRQ/ARQ) sheep were inoculated with CD68⁺ macrophages and 6 (1 ARQ/ARQ and 5 VRQ/ARQ) sheep were inoculated with CD11c⁺ B1 lymphocytes. None of the animals inoculated with platelet-rich plasma developed disease. There was no noticeable effect of donor genotype on the transmission efficiency of scrapie-infected blood components.

Sheep of the VRQ/ARQ and ARQ/ARQ genotypes inoculated with CD11c⁺ B1 lymphocytes and CD68⁺ macrophages revealed genotype-associated differences in PrPSc accumulation in the brain.

Immunohistochemistry was used to determine the effect of varied blood components (e.g. macrophages or B1 lymphocytes), donor genotype and/or recipient genotype on PrPSc deposition in the brain. All scrapie-positive sheep had widespread PrPSc accumulation throughout the brain. The cell type used in the inoculum (e.g. B1 lymphocytes or macrophages) did not noticeably affect PrPSc deposition pattern, but different patterns were observed between ARQ/ARQ and VRQ/ARQ sheep, particularly in rostral areas of the brain.

In caudal brain regions, specifically the medulla at the level of the obex, there was marked particulate and intraneuronal immunolabelling and mild to moderate linear and perineuronal immunolabelling (Fig. 1a). In the cerebellum, there was marked particulate immunolabelling in the granular and molecular cell layers, particularly adjacent Purkinje cells, while linear, stellate and intraglial immunolabelling types were commonly observed in the molecular layer (Fig. 1b).

Genotype-associated differences in PrPSc deposition pattern were most noticeable in rostral brain regions. In particular, there was a difference in the relative amount of immunoreactivity in the grey matter compared to the white matter that was most noticeable in the internal capsule (Fig. 1c, d). In sheep with an ARQ/ARQ genotype, there was more PrPSc in the grey matter than the white matter (Fig. 1c). In two sheep with the VRQ/ARQ genotype, there was more PrPSc in the white matter than the grey matter (#803 and #928); however, on average, sheep with the VRQ/ARQ genotype had similar levels of PrPSc in the white and grey matter at the level of the basal nuclei (Fig. 1d). The pattern of immunoreactivity in the white matter was similar in sheep of both genotypes, with moderate to marked stellate, perivascular, particulate and intraglial immunolabelling types present.

Additionally, the molecular profile of PrPSc from brainstem homogenates was analysed by Western blot to compare the migration patterns of sheep inoculated with CD11c⁺ B1 lymphocytes versus those inoculated with CD68⁺ macrophages that were positive for the scrapie agent. Western
blot analysis revealed a similar banding pattern among sheep inoculated with CD11c⁺ B1 lymphocytes and those inoculated with CD68⁺ macrophages (Fig. 2).

DISCUSSION
In this study we evaluated whether experimental IC inoculation with B1 lymphocytes, macrophages, or platelet-rich plasma from scrapie-infected sheep into susceptible VRQ/ARQ and ARQ/ARQ sheep would result in infection. Three groups of recipient sheep (six VRQ/ARQ and two ARQ/ARQ animals in each group) were inoculated with 0.5 ml of inoculum composed of 10⁶ macrophages, B1 lymphocytes, or platelets derived from either donor sheep S300 or B54. At the completion of the study, four (two ARQ/ARQ and two VRQ/ARQ) of the eight animals (50%) inoculated with macrophages and six (one ARQ/ARQ and five VRQ/ARQ) of the eight animals (75%) inoculated with B1 lymphocytes were determined to be scrapie-positive based on accumulation of pathogenic prion protein (PrPSc) by immunohistochemistry, Western blot, and EIA in CNS and lymphoid tissues [tonsils (palatine and pharyngeal), retropharyngeal and mesenteric lymph node and spleen]. PrPSc was not detected in any of the animals that were inoculated with platelet-rich plasma. This study complements and expands on previously published work that demonstrate scrapie infectivity in whole blood [11, 32] and blood fractions, including peripheral blood mononuclear cells [33, 34], B and T lymphocytes [32, 34] and monocytes [34] (Table 2).

Prion infectivity in CD11c⁺ B1 lymphocytes
Following some of the first evidence of widespread lymphoid accumulation of PrPSc in scrapie-infected animals [1–5, 7–9], many studies have demonstrated an association between PrPSc and immune cells [e.g. follicular dendritic cells (FDCs), B lymphocytes and tingible body macrophages] in a variety of TSEs [9, 23–26]. Specifically, B lymphocytes have been associated with the trafficking and dissemination of PrPSc throughout the lymphoreticular system [25, 35–44]. More recently, Dassanayake et al. and Douet et al. demonstrated scrapie infectivity following intravenous transfusion of CD72⁺, CD21⁺ and CD45⁺ B lymphocytes prepared from sheep naturally and experimentally infected with classical ovine scrapie [32, 33]. In support, Mathiason et al. showed that CD72⁺ B lymphocytes derived from peripheral blood

Fig. 1. Accumulation of PrPSc in the CNS. Representative micrographs show PrPSc immunoreactivity in the brainstem at the level of the obex (a) (scale bar, 50 µm), cerebellum (b) (scale bar, 100 µm), internal capsule of an ARQ/ARQ animal (c) (scale bar, 50 µm), or internal capsule of a VRQ/ARQ animal (d) (scale bar, 100 µm).
prion infection. They suggested that PrPSc in lymphoid tissues and significantly prolonged susceptibility to disease [50]. Functionally, CD11c+ B1 lymphocytes are believed to form the first line of defence in an immune response and are a key source of natural IgM antibodies that respond to self- and repetitive antigen in a T-cell-independent manner [45]. While a humoral response is known to be virtually absent in prion infection, many studies have demonstrated that PrPSc elicits a predominantly IgM response in vivo following repeated immunization [51–53]. In line with these data, our study confirms that CD11c+ B1 lymphocytes derived from scrapie-infected sheep contain sufficient levels of prion infectivity to cause disease in susceptible VRQ/ARQ and ARQ/ARQ sheep, which has not been previously demonstrated.

The positive sheep in the CD11c+B1 lymphocyte group that received B54-derived inoculum had starkly different incubation periods. The incubation period in sheep #949 was 2.1x longer than that in sheep #961. The discrepancy cannot be accounted for by genotype; both sheep were the VRQ/ARQ genotype. One explanation could be human error during inoculum preparation or inoculation procedures. This is unlikely, given the meticulous procedures regarding the preparation and delivery of inocula. Each tube of CD11c+B1 lymphocytes was treated equally: collection, counting and separation into 10 tubes containing 3.66×10^6 cells ml^-1 PBS. The difference between the incubation periods in these animals is less interesting than the long duration of incubation in these sheep. In comparison, sheep with the VRQ/ARQ genotype oronasally inoculated with 0.1 g of 13–7 scrapie have a mean incubation period of 691 days [27]. Sheep with the VRQ/ARQ genotype intracranially inoculated with 0.1 g of 13–7 scrapie have an average incubation period of 428 days (internal unpublished data). The sheep in the present study were also inoculated intracranially, but they have a much longer incubation period. This discrepancy in incubation periods highlights the low levels of PrPSc associated with CD11c+B1 lymphocytes compared to brain homogenate-derived inocula.

**Prion infectivity in CD68+ macrophages**

This study reports that experimental IC inoculation of CD68+ macrophages from scrapie-infected sheep into susceptible VRQ/ARQ and ARQ/ARQ sheep resulted in transmission to four out of eight animals (50%). While their specific role in prion disease pathogenesis has not been elucidated, several studies have implicated antigen-presenting cells (i.e. dendritic cells, B-cells and macrophages) as probable candidates for uptake and transport of PrPSc within the lymphoreticular system [54–60]. In particular, PrPSc has been demonstrated within the lysosomes of splenic tingible body macrophages, which are predominantly found in germinal centres [9, 61] and in dome macrophages found in Peyer’s patches of scrapie-infected mice and sheep [1, 61, 62]. Maignien et al. reported that depletion of macrophages in

---

**Figure 2.** Western blot migration patterns of samples from sheep inoculated with different blood components. Proteinase K digestion of brain homogenates from sheep inoculated with scrapie-infected CD11c+ B1 lymphocytes or CD68+ macrophages reveals three immunoreactive bands that represent three PrPSc glycosylation states. Western blot analysis of PrPSc reveals similar band patterns for scrapie-positive sheep inoculated with CD11c+ B1 lymphocytes (lanes 1, 2) and CD68+ macrophages (lanes 3, 4) derived from either donor sheep S300 or B54, respectively. To highlight the lanes of interest, blots were cropped from different parts of the same gel. Each lane is representative of all animals in that group. M. molecular weight marker.

---

or retropharyngeal lymph nodes can transmit CWD to both native hosts and cervidized mice [26]. The present study expands on these findings in demonstrating that a specific subset of B lymphocytes, CD11c+ cells, can transmit scrapie to susceptible VRQ/ARQ and ARQ/ARQ genotype sheep.

Two subpopulations of B lymphocytes have been characterized in several species, including sheep, with apparent distinctions in morphology, function and anatomical distribution [45, 46]: B1 cells that comprise the majority of sheep peripheral blood B-cells [47, 48] and are distinguished by their expression of CD11b and CD11c [47, 48] and B2 cells that are characterized by their expression of CD21 and CD62L [49]. Edwards et al. demonstrated a direct association of PrPSc in blood with the CD11b/CD11c+ expressing subset of B lymphocytes [48]. To further support the participation of CD11c+-expressing cells in scrapie pathogenesis, a study by Raymond et al. revealed that transient in vivo depletion of migratory CD11c+-expressing cells in

---

or retropharyngeal lymph nodes can transmit CWD to both native hosts and cervidized mice [26]. The present study expands on these findings in demonstrating that a specific subset of B lymphocytes, CD11c+ cells, can transmit scrapie to susceptible VRQ/ARQ and ARQ/ARQ genotype sheep.

Two subpopulations of B lymphocytes have been characterized in several species, including sheep, with apparent distinctions in morphology, function and anatomical distribution [45, 46]: B1 cells that comprise the majority of sheep peripheral blood B-cells [47, 48] and are distinguished by their expression of CD11b and CD11c [47, 48] and B2 cells that are characterized by their expression of CD21 and CD62L [49]. Edwards et al. demonstrated a direct association of PrPSc in blood with the CD11b/CD11c+ expressing subset of B lymphocytes [48]. To further support the participation of CD11c+-expressing cells in scrapie pathogenesis, a study by Raymond et al. revealed that transient in vivo depletion of migratory CD11c+-expressing cells in
Peyer’s patches of scrapie- and BSE-infected mice led to an earlier appearance and increased accumulation of PrP\textsuperscript{Sc} in the lymphoreticular system, further suggesting a key role of macrophages in the sequestration and elimination of infectious PrP\textsuperscript{Sc} [63]. However, to the best of our knowledge, the ability of CD68\textsuperscript{+} macrophages to transmit prion disease has not previously been demonstrated.

Table 2. Summary of scrapie transmission studies of sheep/ovinized mice IV transfused or IC inoculated with different blood components from scrapie-infected sheep. Summary of results from the present study (*). All studies represented in the table used a similar number of cells (~10\textsuperscript{6}) in their inocula. Only one study represented in this table utilized a mouse bioassay: ovine VRQ/VRQ PrP\textsuperscript{Sc} transgenic mice (Tg338) were intracerebrally inoculated with classical scrapie isolate PG127 derived from VRQ/VRQ sheep (†).

| Blood component | Attack rate | Donor | Recipient | Scrapie strain | Route of inoc. | Reference |
|-----------------|-------------|-------|-----------|----------------|----------------|-----------|
| PBMCs           | 4/4         | VRQ/VRQ | VRQ/VRQ | natural        | IV             | [34]      |
|                 | 15/15       | VRQ/VRQ | VRQ/VRQ | natural        | IV             | [33]      |
| CD72\textsuperscript{B} lymphocytes (pan) | 3/3 | VRQ/VRQ | VRQ/VRQ | natural       | IV             | [33]      |
| CD21\textsuperscript{B} lymphocytes | 3/3 | VRQ/VRQ | VRQ/VRQ | natural       | IV             | [33]      |
| CD45\textsuperscript{B} lymphocytes | 4/4 | VRQ/VRQ | VRQ/VRQ | PG127         | IV             | [32]      |
| CD11c B\textsuperscript{I} lymphocytes DCs, and DC precursors | 3/3 | ARQ/ARQ | VRQ/ARQ | US 13–7       | IC             | *         |
|                 | 1/1         | ARQ/ARQ | ARQ/ARQ | US 13–7       | IC             | *         |
|                 | 2/3         | ARQ/ARK | VRQ/ARQ | US 13–7       | IC             | *         |
|                 | 0/1         | ARQ/ARK | ARQ/ARQ | US 13–7       | IC             | *         |
| CD2\textsuperscript{αβ} and γδ T lymphocytes (pan) | 1/4 | VRQ/VRQ | VRQ/VRQ | natural       | IV             | [34]      |
| CD4\textsuperscript{α} and CD8\textsuperscript{α} T lymphocytes | 2/4 | VRQ/VRQ | VRQ/VRQ | PG127         | IV             | [32]      |
| CD4\textsuperscript{1} monocytes | 2/5 | VRQ/VRQ | VRQ/VRQ | natural       | IV             | [34]      |
|                 | 0/4         | VRQ/VRQ | VRQ/VRQ | PG127         | IV             | [32]      |
| CD68\textsuperscript{α} macrophages | 1/3 | ARQ/ARQ | VRQ/ARQ | US 13–7       | IC             | *         |
|                 | 1/1         | ARQ/ARQ | ARQ/ARQ | US 13–7       | IC             | *         |
|                 | 1/3         | ARQ/ARK | VRQ/ARQ | US 13–7       | IC             | *         |
|                 | 1/1         | ARQ/ARK | ARQ/ARQ | US 13–7       | IC             | *         |
| Platelet-rich plasma | 2/3 | ARQ/ARQ | ARQ/ARQ | natural       | IV             | [33]      |
| Platelet-poor plasma | 0/3 | ARQ/ARQ | ARQ/ARQ | natural       | IV             | [33]      |
| Platelets       | 24/27       | VRQ/VRQ\dagger | Tg338\dagger | PG127\dagger | IC             | [64]      |
| Platelet-rich plasma | 0/3 | ARQ/ARQ | VRQ/ARQ | US 13–7       | IC             | *         |
|                 | 0/1         | ARQ/ARQ | ARQ/ARQ | US 13–7       | IC             | *         |
|                 | 0/3         | ARQ/ARK | VRQ/ARQ | US 13–7       | IC             | *         |
|                 | 0/1         | ARQ/ARK | ARQ/ARQ | US 13–7       | IC             | *         |

PBMCs, peripheral blood mononuclear cells that include T-lymphocytes, B-lymphocytes, NK cells and monocytes. Genotype, recipient sheep that were either PRNP homozygous or heterozygous at codon 136 (ARQ/ARQ, VRQ/VRQ, or VRQ/ARQ respectively) or heterozygous (ARQ/ARK) at codon 171.

Prion infectivity in platelets

Thus far, there is inconsistent evidence associating prion infectivity with platelets. In this report, none of the eight animals inoculated with platelet-rich plasma developed scrapie. The ability of TSE-infected platelets to transmit prion disease has been demonstrated in scrapie-infected ovinized
Tg338 mice [64] and sheep [33], BSE-infected sheep [65] and CWD-infected white-tailed deer and cervidized mice [26]. These studies are discrepant with the present work and other observations in hamster scrapie strain 263K [14] and mouse-adapted strains of vCJD or GSS (Fukuoka-1) [36]. Considering that PrPSc serves as a template to convert to additional PrPSc, differences in the distribution of PrPSc on peripheral blood cells of different species may partly account for the variability in infectivity among rodent species vs bovine, ovine and cervid species [14, 20, 26, 66]. Dassanayake et al. demonstrated scrapie infectivity following intravenous trans-fusion of platelet-rich plasma prepared from sheep naturally infected with classical ovine scrapie [33], which contradicts our results. Additional factors may have contributed to this inconsistency and affected scrapie infectivity across studies, including the scrapie strain of the blood donors; route of inoculation; and/or processing of platelets.

Genotype-associated differences in PrPSc accumulation in the brain

Here we report that the cell type used in the inocula (e.g. CD11c+ B1 lymphocytes or CD68+ macrophages) did not noticeably affect PrPSc deposition pattern in the brain; however, different patterns were observed between sheep with the ARQ/ARQ and VRQ/ARQ genotypes, predominantly in rostral areas of the brain. Specifically, sheep with the ARQ/ ARQ genotype had more PrPSc in the grey matter than the white matter (most evident at the level of the basal nuclei), while sheep with the VRQ/ARQ genotype had similar levels of PrPSc in the white and grey matter. The finding of genotype-associated differences in the accumulation of PrPSc in the grey and white matter of recipient sheep after intracranial inoculation has been observed previously [67]. In order to determine whether the disease phenotype was influenced by inoculum cell type, or host versus recipient genotypes, we constructed immunohistochemical PrPSc profiles. PrPSc profiles were generated by scoring the magnitude of distinct morphological immunolabelling types in predefined brain regions, similar to previously described methods [68] (data not shown). Previously published data demonstrated that immunohistochemical PrPSc profiles can be affected by multiple factors, including the TSE strain, host genotype/breed, incubation times [69–73] and, perhaps, donor genotype. Additionally, significant variation in PrPSc profiles among animals of the same breed and genotype has also been described [72]. Due to the low sample size in each host/donor genotype group (n=1–2 animals that tested positive for the scrapie agent), individual animal variation and/or observer variation, in this particular case, it was unreliable to make comparisons based on PrPSc profiles.

Conclusions

In summary, the results reported here confirm that CD11c+ B1 lymphocytes and CD68+ macrophages isolated from sheep inoculated with the US no. 13–7 scrapie agent contained sufficient levels of prion infectivity to cause disease in VRQ/ARQ and ARQ/ARQ genotype sheep. Inconsistent evidence associating prion infectivity with platelets may be explained by the variability in surface PrPc expression levels of various blood fractions of rodent species vs bovine, ovine and cervid species that could modify a cell subset’s ability to accumulate and/or replicate the prion agent; scrapie strain of the blood donors; route of inoculation; and/or processing of platelets. Whether these blood components are critical to prion pathogenesis has not been elucidated, but this work indicates that prion infectivity in CD11c+ B1 lymphocytes and CD68+ macrophages was sufficient to cause disease and likely to play a role in haematogenous prion spread. Consistent with this, previous reports have shown that leukoreduction reduced blood-borne prion infectivity [74, 75]. Furthermore, the concentration of prions in whole blood is low [21, 22], and so direct diagnostic tests are unreliable. Enrichment of B1 lymphocytes and macrophages may significantly improve the detection of prion infectivity in blood for enhanced or perhaps early diagnosis. These results provide a starting point for further investigation on the role of CD11c+ B1 lymphocytes, CD68+ macrophages and platelets in disease progression in sheep and other natural hosts of prion disease.

Funding information

This research was supported in part by an appointment to the Agricultural Research Service (ARS) Research Participation Program administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy (DOE) and the US Department of Agriculture (USDA). ORISE is managed by ORAU under DOE contract number DE-SC0014664. All opinions expressed in this paper are the authors’ and do not necessarily reflect the policies and views of USDA, ARS, DOE, or ORAU/ORISE. This research was funded in its entirety by congressionally appropriated funds to the United States Department of Agriculture, Agricultural Research Service. The funders of the work did not influence study design, data collection and analysis, decision to publish, or the preparation of the manuscript.

Acknowledgements

The authors wish to thank Martha Church, Rylie Frese, Kevin Hassall, Joe Lesan, Leisa Mandell and Trudy Tatum for technical support.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical statement

This study was done in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Washington, DC, USA) and the Guide for the Care and Use of Agricultural Animals in Research and Teaching (Federation of Animal Science Societies, Champaign, IL, USA). The protocol was approved by the Institutional Animal Care and Use Committee at the National Animal Disease Center (protocol number: 3892).

References

1. Heggebo R, Press CM, Gunnes G, Inge Lie K, Tranulis MA et al. Distribution of prion protein in the ileal Peyer’s patch of scrapie-free lambs and lambs naturally and experimentally exposed to the scrapie agent. J Gen Virol 2000;81:2327–2337.
2. Jeffrey M, González L, Espenes A, Press CM, Martin S et al. Trans- portation of prion protein across the intestinal mucosa of scrapie-susceptible and scrapie-resistant sheep. J Pathol 2006;209:4–14.
3. Andréatiletti O, Berthon P, Marc D, Sarradin P, Grosclaude J et al. Early accumulation of PrP(Sc) in gut-associated lymphoid and nervous tissues of susceptible sheep from a Romanov flock with natural scrapie. J Gen Virol 2000;81:3115–3126.
4. Muramatsu Y, Onodera A, Horuchi M, Ishiguro N, Shinagawa M. Detection of PrPSc in sheep at the preclinical stage of scrapie and its significance for diagnosis of insidious infection. Arch Virol 1994;134:427–432.

5. Race R, Ernst D, Jenny A, Taylor W, Sutton D et al. Diagnostic implications of detection of proteinase K-resistant protein in spleen, lymph nodes, and brain of sheep. Am J Vet Res 1992;53:883–889.

6. Greenlee JJ, Greenlee MHW. The transmissible spongiform encephalopathies of livestock. Iar J 2015;56:7–25.

7. Eklund CM, Kennedy RC, Hadlow WJ. Pathogenesis of scrapie virus infection in the mouse. J Infect Dis 1967;117:15–22.

8. Fraser H, Dickinson AG. Pathogenesis of scrapie in the mouse: the role of the spleen. Nature 1970;226:442–463.

9. Jeffrey M, McGovern G, Goodsrn CM, Brown KL, Bruce ME. Sites of prion protein accumulation in scrapie-infected mouse spleen revealed by immuno-electron microscopy. J Pathol 2000;191:323–332.

10. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. The Lancet 2000;356:999–1000.

11. Andréoletti O, Litaise C, Simmons H, Corbière F, Lugan S et al. Highly efficient prion transmission by blood transfusion. PLoS Pathog 2012;8:e1002782.

12. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002;83:2897–2905.

13. Mathiason CK, Hays SA, Powers J, Hayes-Clarke J, Langen- burg J et al. Infectious prions in pre-clinical deer and transmission of chronic wasting disease solely by environmental exposure. PLoS One 2009;4:e5916.

14. Holada K, Vostal JG, Theisen PW, MacAuley C, Gregori L et al. Scrapie infectivity in hamster blood is not associated with platelets. J Virol 2002;76:4469–4460.

15. Gregori L, Rohwer RG. Characterization of scrapie-infected and normal hamster blood as an experimental model for TSE-infected human blood. Dev Biol 2007;277:123–133.

16. Gregori L, Lambert BC, Gurgel PV, Lathrop JT, Edwardsson P, Lambert BC et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006;368:2226–2230.

17. Gregori L, Lambert BC, Gurgel PV, Gheorghiu L, Edwardsson P et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion 2006;46:1152–1161.

18. Kuroda Y, Gibbs CJ, Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983;41:154–161.

19. Manouselis EE, Kim JH, Mericangas JR, Manouselis L. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet 1985;2:896–897.

20. Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995;2:472–477.

21. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998;38:810–816.

22. Brown P, Cervenáková L, McShane LM, Barber P, Rubenstein R et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999;39:1169–1178.

23. McBride PA, Eikeleenboom P, Kraal G, Fraser H, Bruce ME. Prp protein is associated with follicular dendritic cells of spleens and lymph nodes in uninfected and scrapie-infected mice. J Pathol 1992;168:413–418.

24. Muramoto T, Kitamoto T, Tateishi J, Goto I. The sequential developmental pattern of abnormal prion protein accumulation in mice with Creutzfeldt-Jakob disease. Am J Pathol 1992;140:1411.

25. Sigurdson CJ, Barillas-Mury C, Miller MW, Oesch B, van Keulen LJ et al. PrPCWD lymphoid cell targets in early and advanced chronic wasting disease of mule deer. J Gen Virol 2002;83:2617–2628.

26. Mathiason CK, Hayes-Clarke J, Hays SA, Powers J, Osborn DA et al. B cells and platelets harbor prion infectivity in the blood of deer infected with chronic wasting disease. J Virol 2010;84:5097–5107.

27. Moore SJ, Smith JD, Greenlee MHW, Nicholson EM, Richt JA et al. Comparison of two us sheep scrapie isolates identifies differentiation as separate strains. Vet Pathol 2016;53:1187–1196.

28. Hamir AN, Kunkle RA, Richt JA, Greenlee JJ, Miller JM. Serial passage of scrapie inoculum in Suffolk sheep. Vet Pathol 2009;46:39–44.

29. Hamir AN, Miller JM, Stack MJ, Chaplin MJ. Failure to detect abnormal prion protein and scrapie-associated fibrils in the blood after intracerebral inoculation of genetically susceptible sheep with scrapie agent. Can J Vet Res 2002;66:289.

30. Spraker TR, O’Rourke KL, Balachandran A, Zink RR, Cummings BA et al. Validation of monoclonal antibody F99/97.6.1 for immunohistochemical staining of brain and tonsil in mule deer (Odocoileus hemionus) with chronic wasting disease. J Vet Diag Invest 2002;14:3–7.

31. Greenlee JJ, Zhang X, Nicholson EM, Kunkle RA, Hamir AN. Prolonged incubation time in sheep with prion protein containing lysine at position 171. J Vet Diag Invest 2012;24:556–558.

32. Douet-JL, Lacroix C, Litaise C, Lugan S, Corbière F et al. Monoclonal antibody staining of brain and tonsil in mule deer (Odocoileus hemionus) with chronic wasting disease. J Vet Diag Invest 2012;24:556–558.

33. Dassanayake RP, Schneider DA, Truscott TC, Young AJ, Zhung D et al. Classical scrapie prions in ovine blood are associated with B lymphocytes and platelet-rich plasma. BMC Vet Res 2011;7:75.

34. Dassanayake RP, Madsen-Bouterse SA, Truscott TC, Zhung D, Mousel MR et al. Classical scrapie prions are associated with peripheral blood monocytes and T-lymphocytes from naturally infected sheep. BMC Vet Res 2016;12:27.

35. Casaccia P, Ladogana A, Xi YG, Pocchiari M. Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Arch Virol 1989;108:145–149.

36. Cervenáková L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003;43:1687–1694.

37. Glatzel M, Abela E, Maissen M, Aguzzi A. Extranepathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003;349:1812–1820.

38. Herzog C, Rivière J, Lessoucura-Etchegary N, Charbonnier A, Leblanc V et al. PrPfse distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol 2005;79:14339–14345.

39. Klein MA, Frigg R, Flechsig E, Raebere AJ, Kalinke U et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997;390:687–690.

40. McGovern G, Jeffrey M. Scrapie-specific pathology of sheep lymphoid tissues. PLoS One 2007;2:e1304.

41. Zabel MD, Heikenwalder M, Prinz M, Arriggi I, Schwarz P et al. Stromal complement receptor CD21/35 facilitates lymphoid prion colonization and pathogenesis. J Immunol 2007;179:6144–6152.

42. Mok SWF, Proia RL, Brinkmann V, Mabbott NA. B cell-specific S1PR1 deficiency blocks prion dissemination between secondary lymphoid organs. J Immunol 2012;188:5032–5040.

43. Frigg R, Klein MA, Hegyi I, Zinkernagel RM, Aguzzi A. Scrapie pathogenesis in subclinically infected B-cell-deficient mice. J Virol 1999;73:9584–9588.

44. von Poser-Klein C, Flechsig E, Hoffmann T, Schwarz P, Harms H et al. Alteration of B-cell subsets enhances neuroinvasion in mouse scrapie infection. J Virol 2008;82:3791–3795.
56. Gupta VK, McConnell I, Dalziel RG, Hopkins J. Two B cell subpopulations have distinct recirculation characteristics. *Eur J Immunol* 1998:28:1597–1603.

47. Rhun L. B1-like cells exist in sheep. Characterization of their phenotype and behavior. *Immunol* 1998:95:178–184.

52. Edwards JC, Moore SJ, Hawthorn JA, Neale MH, Terry LA. PrP(Sc) is associated with B cells in the blood of scrapie-infected sheep. *Virology* 2010:405:110–119.

49. Young AJ, Marston WL, Dessing M, Dudler L, Heim WR. Distinct recirculating and non-recirculating B-lymphocyte pools in the peripheral blood are defined by coordinated expression of CD21 and L-selectin. *Blood* 1997:90:4865–4875.

53. Korth M, Aucouturier P, Mabott NA. In vivo depletion of CD11c+ cells impairs scrapie agent neuroinvasion from the intestine. *J Immunol* 2007:179:7758–7766.

54. Korth C, Siefert B, Streit P, Moser M, Schaller O et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. *Nature* 1997:390:74–82.

55. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL et al. A prion protein epitope selective for the pathologically misfolded conformation. *Nat Med* 2003:9:893–900.

56. Tayebi M, Enever P, Sattar Z, Collinge J, Hawke S. Disease-associated prion protein elicits immunoglobulin M responses in vivo. *Mol Med* 2004:10:104–111.

57. Aucouturier P, Geissmann F, Damotte D, Saborio GB, Meeker HC et al. Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. *J Clin Invest* 2001:108:703–708.

58. Flores-Lanagaric A, Sebti Y, Mitchell DA, Sim RB, MacPherson GG. Scapie pathogenesis: the role of complement C1q in scrapie agent uptake by conventional dendritic cells. *J Immunol* 2009:182:1305–1313.

59. Huang F-P, Farquhar CF, Mabott NA, Bruce ME, MacPherson GG. Migrating intestinal dendritic cells transport PrP(Sc) from the gut. *J Gen Virol* 2002:83:267–271.

60. Luhr KM, Wallin RPA, Ljunggren H-G, Löw P, Taraboulos A et al. Processing and degradation of exogenous prion protein by CD11c+ myeloid dendritic cells in vitro. *J Virol* 2002:76:12259–12264.

61. Sethi S, Kerkseki KM, Brocker T, Kretzschmar H. Role of the CD8+ dendritic cell subset in transmission of prions. *J Virol* 2007:81:4877–4880.

62. Beebes M, McBride PA. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies. *Fibres J* 2007:274:588–605.

63. Mabott NA, MacPherson GG. Prions and their lethal journey to the brain. *Nat Rev Microbiol* 2006;4:201–.

64. van Keulen LJ, Vromans MEW, van Zijderveld FG. Early and late pathogenesis of natural scrapie infection in sheep. *APMIS* 2002;110:23–32.

65. Heggebo R, Press CM, Gunnes G, González L, Jeffrey M. Distribution and accumulation of PrP in gut-associated and peripheral lymphoid tissue of scrapie-affected Suffolk sheep. *J Gen Virol* 2002:83:479–489.

66. Maignien T, Shakweh M, Calvo P, Marcé D, Salès N et al. Role of gut macrophages in mice orally contaminated with scrapie or BSE. *Int J Pharm* 2005:298:293–304.

67. Lacroux C, Vilette D, Fernández-Borges N, Litaise C, Lunag S et al. Prionemia and leukocyte-platelet-associated infection in sheep transmissible spongiform encephalopathy models. *J Virol* 2012:86:2056–2066.

68. McCutcheon S, Alejo Blanco AR, Houston EF, de Wolf C, Tan BC et al. All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD. *PLoS One* 2011;6:e23169.

69. Bons N, Lehmann S, Mestre-Françès N, Dormont D, Brown P. Brain and Buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. *Transfusion* 2002:42:513–516.

70. Cassmann ED, Moore SJ, Smith JD, Greenlee JJ. Sheep with the homozygous Lysine-171 prion protein genotype are resistant to classical scrapie after experimental oronasal inoculation. *Vet Pathol* 2019:6:409–417.

71. Sió S, Jeffrey M, Martin S, Chianini F, Dagleish MP et al. Characterization of strains of ovine transmissible spongiform encephalopathy with a short PrPd profiling method. *J Comp Pathol* 2010:142:300–310.

72. González L, Martin S, Begara-McGorium I, Hunter N, Houston F et al. Effects of agent strain and host genotype on PrP accumulation in the brain of sheep naturally and experimentally affected with scrapie. *J Comp Pathol* 2002:126:17–29.

73. González L, Pitarch JL, Martin S, Thurston L, Simmons H et al. Influence of polymorphisms in the prion protein gene on the pathogenesis and neuropathological phenotype of scrapie after oral infection. *J Comp Pathol* 2014:150:57–70.

74. Ligios C, Jeffrey M, Ryder SJ, Bellwormy SJ, Simmons MM. Distinction of scrapie phenotypes in sheep by lesion profiling. *J Comp Pathol* 2002:127:45–57.

75. Begara-McGorium I, González L, Simmons M, Hunter N, Houston F et al. Vascular lesion profile in sheep scrapie: factors influencing its variation and relationship to disease-specific PrP accumulation. *J Comp Pathol* 2002:127:45–57.

76. Jeffrey M, González L. Classical sheep transmissible spongiform encephalopathies: pathogenesis, pathological phenotypes and clinical disease. *Neuropathol Appl Neurobiol* 2007:33:373–394.

77. Gregori L, McCombie N, Palmer D, Birch P, Sovemimo-Coker SO et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. *The Lancet* 2004;364:529–531.

78. Prowse CV, Bailey A. Validation of prion removal by leucocyte-depleting filters: a cautionary tale. *Vox Sang* 2000;79:248.